Comparison of Therapeutic Results with/without Additional Hyperbaric Oxygen Therapy in Idiopathic Sudden Sensorineural Hearing Loss: A Randomized Prospective Study.

Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Jilin University, Jilin, China. Division of Ear, Nose and Throat Diseases, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. Department of Otolaryngology Head and Neck Surgery, The People's Hospital of Macheng City, Macheng, China. Department of Otolaryngology, Head and Neck Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China. Department of Otolaryngology, West China Hospital, Sichuan University, Chengdu, China. Department of Otolaryngology Head and Neck, Karolinska Institutet, Stockholm, Sweden. Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China, maoli.duan@ki.se. Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Jilin University, Jilin, China, maoli.duan@ki.se. Division of Ear, Nose and Throat Diseases, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden, maoli.duan@ki.se. Department of Otolaryngology Head and Neck, Karolinska Institutet, Stockholm, Sweden, maoli.duan@ki.se.

Audiology & neuro-otology. 2021;(1):11-16

Abstract

OBJECTIVE To assess the efficacy of the combination of hyperbaric oxygen (HBO) and pharmacological treatment in patients with idiopathic sudden sensorineural hearing loss (ISSNHL) and define patients amenable for HBO therapy. METHODS Prospective, randomized, trial involving 136 cases with unilateral ISSNHL that were randomly divided into 2 groups: the pharmacological treatment (P) group and HBO + pharmacological treatment (HBO+P) group, which received additional HBO for 14 days besides the pharmacological treatments. Pure tone audiometry gain larger than 15 dBHL was defined as success, and the success rate of each group was calculated. RESULTS The overall success rate of the HBO+P group and the P group is 60.6% (40/66) and 42.9% (30/70), respectively (p < 0.05). Furthermore, patients with mild-moderate baseline hearing loss, aged ≤50 years, receiving treatment in ≤14 days, or without accompanied dizziness/vertigo in the HBO+P group had higher success rate than the P group (p < 0.05). CONCLUSIONS HBO combined with pharmacological treatments leads to better hearing recovery than pharmacological treatments alone.

Methodological quality

Metadata